Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
ScemblixⓇ continues strong launch momentum in Q3
1
GROWTH
• SCEMBLIX®
Strong early launch uptake
☑ $41m Q3 sales driven by patients with
resistance/intolerance to other TKIs
Future growth drivers
US
Accelerated approval converted to
regular approval based on 96wk data
✓ 13%
3L+ total patient share¹,
2x ponatinib in 8 months.
Global
Rollout ongoing with EU approval in Q3;
strong early uptake in JP and UK
✓ 39%
3L+ new patient share1
1L
Ph3 study enrolling ahead of plan,
readout expected H2 2024
TKI Tyrosine Kinase Inhibitor 1. IQVIA Market Sizing "Source of Business" and "Product Summary" reports as of September 2022.
14 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation